| Brett Donahey, DO | |
|
7000 Parkwood Blvd Ste B200, Frisco, TX 75034-7446 | |
| (214) 705-1900 | |
| Not Available |
| Full Name | Brett Donahey |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 23 Years |
| Location | 7000 Parkwood Blvd Ste B200, Frisco, Texas |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023044690 | NPI | - | NPPES |
| 200262580A | Medicaid | KS | |
| 103833 | Other | KS | BCBS OF KANSAS |
| P00116544 | Other | RR MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 30406 (Kansas) | Secondary |
| 207Q00000X | Family Medicine | N2472 (Texas) | Primary |
| Entity Name | Morning Light Family Medicine, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063782027 PECOS PAC ID: 1951536200 Enrollment ID: O20131023000438 |
News Archive
Today, as part of its commitment to strengthening health information systems and improving health, especially in the context of the COVID-19 pandemic, WHO announced a new approach to improving access to life-saving data: the SCORE for Health Data Technical Package.
In an article by Egan et al, titled, "Cyclooxygenases, Thromboxane, and Atherosclerosis," published in the Jan 17 issue of Circulation: Journal of the American Heart Association researchers examined some of the molecular mechanisms of drugs affecting prostaglandin and thromboxane production.
In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.
Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.
A new guidance statement from the American Society of Clinical Oncology and the American Academy of Hospice and Palliative Medicine is being presented for the first time at the 2015 Palliative Care in Oncology Symposium in Boston.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brett Donahey, DO 7000 Parkwood Blvd, Ste B200, Frisco, TX 75034-7446 Ph: (620) 421-0600 | Brett Donahey, DO 7000 Parkwood Blvd Ste B200, Frisco, TX 75034-7446 Ph: (214) 705-1900 |
News Archive
Today, as part of its commitment to strengthening health information systems and improving health, especially in the context of the COVID-19 pandemic, WHO announced a new approach to improving access to life-saving data: the SCORE for Health Data Technical Package.
In an article by Egan et al, titled, "Cyclooxygenases, Thromboxane, and Atherosclerosis," published in the Jan 17 issue of Circulation: Journal of the American Heart Association researchers examined some of the molecular mechanisms of drugs affecting prostaglandin and thromboxane production.
In the quest to arrest the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal instruction manual. In a new study, a team led by Dana-Farber Cancer Institute scientists has created the first molecule able to prevent cancer genes from "hearing" those instructions, stifling the cancer process at its root.
Otsuka Pharmaceutical Co., Ltd. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Deltyba (delamanid) in combination with a WHO recommended optimized background regimen for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB). The CHMP opinion will help form the basis for a European Commission decision expected early next year.
A new guidance statement from the American Society of Clinical Oncology and the American Academy of Hospice and Palliative Medicine is being presented for the first time at the 2015 Palliative Care in Oncology Symposium in Boston.
› Verified 3 days ago
Christina Holtz, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5858 W Main St Ste 130, Frisco, TX 75033 Phone: 214-387-4073 Fax: 214-387-8395 | |
Mohita Anil Patel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 9255 Dallas Pkwy Ste 110, Frisco, TX 75033 Phone: 972-377-1490 Fax: 972-377-1499 | |
Dr. Bradley Ryan Friedman, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 11560 Teel Pkwy, Suite #100, Frisco, TX 75034 Phone: 972-668-0821 | |
Avneet Kaur Bajwa, FNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5350 Independence Pkwy Ste 120, Frisco, TX 75035 Phone: 214-888-2244 | |
Amar N Patel, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 9205 Legacy Dr, Frisco, TX 75033 Phone: 972-668-6020 | |
Amylie Rojas, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4461 Coit Rd Ste 301, Frisco, TX 75035 Phone: 469-800-6120 |